Albumin News and Research

RSS

Simple urine test can help identify disease risks in young type 1 diabetes patients

Using a simple urine test, researchers can now identify young people with type 1 diabetes at risk of heart and kidney disease. The new research, funded by JDRF, Diabetes UK, and the British Heart Foundation, was published today, 06 November, in the journal Diabetes Care.

7 Nov 2013

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the initiation of a multinational Phase II clinical study of GKT137831 in patients with diabetic nephropathy.

5 Nov 2013

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

...

23 Oct 2013

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

...

22 Oct 2013

Novozymes Biopharma partners with Almac to provide combined service for drug development

Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, is delighted to announce its new collaboration with Almac, to provide a combined service for drug development applications in the field of drug targeting and pharmacokinetic improvements.

22 Oct 2013

Recombinant hormone could REPLACE calcium supplements

Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.

18 Oct 2013

NEJM publishes Celgene’s Abraxane phase III study results

Published today in the New England Journal of Medicine, a phase III clinical trial of Abraxane (paclitaxel formulated as albumin-bound nanoparticles) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone [(median of 8.5 vs. 6.7 months) (HR 0.72, P=0.000015)].

17 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

Ampio Pharmaceuticals announces financing transaction of $25 million

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a financing transaction that will provide $25 million in gross proceeds to the Company. The financing is a registered direct placement of common stock of the Company.

26 Sep 2013

Supporting the Study of Healthy Aging through Biodevelopment

In this interview, Jacko Duker talks about the Lifelines Project, and how Panasonic ULT freezers have been employed to keep irreplaceable samples safe.

From PHC Europe B.V. 12 Sep 2013

Doubt cast on worth of BP load

Blood pressure load may not be a useful clinical measure, say researchers.

9 Sep 2013

FDA approves ABRAXANE chemotherapy drug for treatment of metastatic pancreatic cancer

The Pancreatic Cancer Action Network is pleased to announce that today ABRAXANE® was approved by the U.S. Food and Drug Administration (FDA) to treat metastatic pancreatic cancer.

7 Sep 2013

Abraxane drug gets FDA approval for patients with advanced pancreatic cancer

The U.S. Food and Drug Administration today approved Abraxane for patients with advanced pancreatic cancer, following 7 years of rigorous clinical trials overseen by Scottsdale Healthcare and the Translational Genomics Research Institute.

7 Sep 2013

Acute manic episodes linked to increased edema risk

Bipolar disorder patients admitted to hospital with a manic episode are at an increased risk for lower limb edema, compared with their peers with depressive or non-affective psychosis episodes, study findings show.

5 Sep 2013

Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC

Albumin-bound paclitaxel plus carboplatin is an effective and well-tolerated first-line treatment in patients with advanced non-small-cell lung cancer, irrespective of histology, study results show.

29 Aug 2013

Research finding could lead to potential treatment for lymphedema

The molecule interleukin-7 is an important immune messenger protein which ensures that a sufficient number of T cells are present in our body for immune defence. Researchers from ETH Zurich have now demonstrated that IL-7 has another important function: it enhances the drainage function of lymphatic vessels, which collect fluid that has leaked out of blood vessels into the body tissue and return it to the bloodstream.

27 Aug 2013

Smartphone-based portable device to conduct kidney tests invented at UCLA

A lightweight and field-portable device invented at UCLA that conducts kidney tests and transmits data through a smartphone attachment may significantly reduce the need for frequent office visits by people with diabetes and others with chronic kidney ailments.

26 Aug 2013

High levels of urinary albumin-to-creatinine ratio linked with greater risk of CHD in black individuals

In a large national study, higher levels of the urinary albumin-to-creatinine ratio was associated with greater risk of incident but not recurrent coronary heart disease in black individuals when compared with white individuals, according to a study in the August 21 issue of JAMA.

21 Aug 2013

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease.

25 Jul 2013

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Baxter International Inc. today announced data featuring ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], a leading recombinant treatment available worldwide, during the 24th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Amsterdam, The Netherlands.

From Baxter International Inc. 5 Jul 2013

Albumin News and Research

Simple urine test can help identify disease risks in young type 1 diabetes patients

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

Novozymes Biopharma partners with Almac to provide combined service for drug development

Recombinant hormone could REPLACE calcium supplements

NEJM publishes Celgene’s Abraxane phase III study results

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Ampio Pharmaceuticals announces financing transaction of $25 million

Supporting the Study of Healthy Aging through Biodevelopment

Doubt cast on worth of BP load

FDA approves ABRAXANE chemotherapy drug for treatment of metastatic pancreatic cancer

Abraxane drug gets FDA approval for patients with advanced pancreatic cancer

Acute manic episodes linked to increased edema risk

Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC

Research finding could lead to potential treatment for lymphedema

Smartphone-based portable device to conduct kidney tests invented at UCLA

High levels of urinary albumin-to-creatinine ratio linked with greater risk of CHD in black individuals

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

Data shows individualized regimens can help optimize prophylaxis treatment in hemophilia patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News